Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Lung Cancer

  Free Subscription


22.06.2026

1 AJR Am J Roentgenol
1 Am J Respir Crit Care Med
2 Ann Surg Oncol
3 Arch Bronconeumol
2 BMC Cancer
1 Cancer Cell
2 Cancer Lett
1 Cancer Res
1 Cancer Sci
1 Chest
2 Clin Cancer Res
4 Clin Lung Cancer
2 Eur J Cancer
1 Eur Respir J
2 Int J Radiat Oncol Biol Phys
1 J Immunol
2 J Natl Cancer Inst
1 J Nucl Med
1 Lancet Oncol
13 Lung Cancer
1 Mol Carcinog
1 Nat Genet
2 Nat Med
2 Oncologist
1 PLoS Biol
1 PLoS One
2 Proc Natl Acad Sci U S A
2 Thorax


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. BROOKS MA
    Artificial Intelligence Is Not a Panacea: LungIMPACT Trial Shows Prioritization Cannot Overcome Systemic Delays in Lung Cancer Diagnosis.
    AJR Am J Roentgenol. 2026 Jun 17. doi: 10.2214/AJR.26.35373.
    PubMed        


    Am J Respir Crit Care Med

  2. PAPAVASSILIOU KA, Stravopodis DJ, Gogou VA, Papavassiliou AG, et al
    Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions.
    Am J Respir Crit Care Med. 2026;212:1100-1114.
    PubMed         Abstract available


    Ann Surg Oncol

  3. TANE S, Nomura K, Watanabe T, Takamori S, et al
    Preoperative Predictors of Surgical Complexity After Neoadjuvant Immunochemotherapy in Non-small-cell Lung Cancer.
    Ann Surg Oncol. 2026 Jun 17. doi: 10.1245/s10434-026-19946.
    PubMed         Abstract available

  4. AIYAMA T, Kakisaka T, Shichi S, Sakamoto Y, et al
    ASO Author Reflections: Prognostic Biomarkers for Surgical Selection in Pulmonary Metastases from Hepatocellular Carcinoma.
    Ann Surg Oncol. 2026 Jun 15. doi: 10.1245/s10434-026-19958.
    PubMed        


    Arch Bronconeumol

  5. CANDAL-PEDREIRA C, Ruano-Ravina A, Calvo de Juan V, Cobo M, et al
    Clinical Characteristics and Survival Outcomes in Patients With Small Cell Lung Cancer in Spain: An Analysis of the Thoracic Tumor Registry (2016-2025).
    Arch Bronconeumol. 2026 Jun 4:S0300-2896(26)00209.
    PubMed         Abstract available

  6. GOROSPE-SARASUA L, van Zeller C, Gomez-de-la-Fuente E
    Incidental Diagnosis of SAPHO Syndrome During Lung Cancer Screening With Low-Dose Thoracic CT.
    Arch Bronconeumol. 2026 Jun 4:S0300-2896(26)00205.
    PubMed        

  7. PORCEL JM, Hidalgo I, Marques M, Parisi E, et al
    Pleural Fluid Outperforms Plasma for Detection of Clinically Relevant Mutations in Lung Cancer-Associated Malignant Pleural Effusion.
    Arch Bronconeumol. 2026 Jun 3:S0300-2896(26)00199.
    PubMed         Abstract available


    BMC Cancer

  8. LI F, Zhang W, Gong X, Liu D, et al
    CD109 is associated with an immunosuppressive microenvironment and M2 macrophage polarization: pan-cancer analysis and functional validation.
    BMC Cancer. 2026;26:760.
    PubMed         Abstract available

  9. SHI L, Fei K, Liu M, Zhou C, et al
    Developing a quality evaluation indicator system for lung cancer diagnosis and treatment: a modified Delphi method study.
    BMC Cancer. 2026 Jun 16. doi: 10.1186/s12885-026-15938.
    PubMed         Abstract available


    Cancer Cell

  10. LIAO J, Yao W, Yu Y, Li A, et al
    Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.
    Cancer Cell. 2026 Jun 18:S1535-6108(26)00265-5. doi: 10.1016/j.ccell.2026.
    PubMed         Abstract available


    Cancer Lett

  11. WANG C, Dong X, Zhang G, Ren N, et al
    Plasma metabolomics enhances risk prediction for lung cancer: a population-based validation study.
    Cancer Lett. 2026;656:218676.
    PubMed         Abstract available

  12. YAN P, Jiang W, Xue X, Hou T, et al
    Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.
    Cancer Lett. 2026;656:218678.
    PubMed         Abstract available


    Cancer Res

  13. FANE ME, Zabransky DJ
    Stress Tested: Aging Rewires Tumors for Metastatic Spread through Activation of the Integrated Stress Response.
    Cancer Res. 2026;86:2834-2836.
    PubMed         Abstract available


    Cancer Sci

  14. TERAMOTO K, Kaku R, Igarashi T, Hashimoto M, et al
    Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non-Small Cell Lung Cancer.
    Cancer Sci. 2026 Jun 12. doi: 10.1111/cas.70446.
    PubMed         Abstract available


    Chest

  15. DIESLER R, Han T, Steagall WK, Salem S, et al
    High-Throughput Proteomics in Lymphangioleiomyomatosis: Premelanosome Protein as a Diagnostic Biomarker, Construction of a Diagnosis Score, and Evidence of Neutrophil Involvement.
    Chest. 2026;169:1599-1615.
    PubMed         Abstract available


    Clin Cancer Res

  16. ZENG Z, Huang W, Zeng F, Xiong L, et al
    The Efficacy and Safety of Tislelizumab plus Anlotinib as First-line Treatment in Advanced Pulmonary Sarcomatoid Carcinoma: A Single-Arm Phase II Trial.
    Clin Cancer Res. 2026;32:2372-2380.
    PubMed         Abstract available

  17. JIMENEZ M, Hatton BA, Moreno-Gonzalez A, Iding JS, et al
    Pulsed Electric Field Ablation Reprograms Tumor Immunity and Stimulates Germinal Center Formation in Tertiary Lymphoid Structures in Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jun 17. doi: 10.1158/1078-0432.CCR-25-3847.
    PubMed         Abstract available


    Clin Lung Cancer

  18. BUSHARA O, Farooq MS, Ahn S, Marostica E, et al
    Treatment Attrition From Surgery to Adjuvant Therapy in Stage IIB and IIIA Lung Adenocarcinoma: A National Cancer Database Analysis.
    Clin Lung Cancer. 2026;27:106-113.
    PubMed         Abstract available

  19. RUICCI KM, Li GJ, Warner A, Youssef A, et al
    Off-Protocol Radiotherapy in Prospective Systemic Therapy Trials for Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2026;27:58-63.
    PubMed         Abstract available

  20. GARASSINO MC, Cousin S, Besse B, Sacher A, et al
    ENTREE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.
    Clin Lung Cancer. 2026;27:65-76.
    PubMed         Abstract available

  21. YERIGERI K, Sengupta M, Zhang J, Puthiamadathil J, et al
    Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma.
    Clin Lung Cancer. 2026;27:77-86.
    PubMed         Abstract available


    Eur J Cancer

  22. PIOTROWSKA Z, Goldberg SB, Goldman JW, de Langen AJ, et al
    Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.
    Eur J Cancer. 2026;242:116807.
    PubMed         Abstract available

  23. LAVIGNE D, Le Pechoux C, Botticella A, Planchard D, et al
    Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.
    Eur J Cancer. 2026;243:116881.
    PubMed         Abstract available


    Eur Respir J

  24. BAKER JR, Beaulieu D, Avci E, Huang E, et al
    Hallmarks of the ageing lung: 10 years later.
    Eur Respir J. 2026;67:2501272.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  25. LIN R, Chen M, Zhang X, Xu T, et al
    Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription.
    Int J Radiat Oncol Biol Phys. 2026;125:949-958.
    PubMed         Abstract available

  26. LI X, Wu Y, Zhang Y, Ge M, et al
    Dosimetric Parameters of the Heart and Its Substructures in Predicting Cardiac Events or Survival in Lung Cancer Patients After Radiotherapy: A Systematic Review and Meta-Analysis.
    Int J Radiat Oncol Biol Phys. 2026 Jun 13:S0360-3016(26)00839.
    PubMed         Abstract available


    J Immunol

  27. LINDAU PL, Nesta AV, Roe CE, Landis MD, et al
    Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy.
    J Immunol. 2026;215:vkag120.
    PubMed         Abstract available


    J Natl Cancer Inst

  28. CHEN TY, Chien LH, Jiang SS, Choi J, et al
    Identifying expression and DNA methylation biomarkers for lung adenocarcinoma risk in East Asia.
    J Natl Cancer Inst. 2026;118:1032-1045.
    PubMed         Abstract available

  29. HARRISON NJ, Rankin NM, Paul CL, Bowden JA, et al
    Implementation of smoking cessation interventions in real-world lung cancer screening: a RE-AIM-guided scoping review.
    J Natl Cancer Inst. 2026 Jun 9:djag102. doi: 10.1093.
    PubMed         Abstract available


    J Nucl Med

  30. BARBER AR, Edwards RS, Dos Santos SN, Emanuelli A, et al
    Imaging xCT with Immuno-PET in Therapy-Resistant Non-Small Cell Lung Cancer.
    J Nucl Med. 2026 Jun 18:jnumed.126.272920. doi: 10.2967/jnumed.126.272920.
    PubMed         Abstract available


    Lancet Oncol

  31. LI Z, Hu J, Chen J, Yu Y, et al
    Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026 Jun 15:S1470-2045(26)00090.
    PubMed         Abstract available


    Lung Cancer

  32. GARCIA-PELAEZ B, Jordana-Ariza N, Aguilar-Hernandez A, Estrada-Tejedor R, et al
    Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report.
    Lung Cancer. 2026;218:109489.
    PubMed         Abstract available

  33. ZHAO W, Guan M, Zhang H, Chen X, et al
    Clinical outcomes and tumor immune microenvironment in SMARCA4-Deficient NSCLC: A Real-World retrospective study.
    Lung Cancer. 2026;217:109414.
    PubMed         Abstract available

  34. KANO M, Furusawa A, Takao S, Suzuki M, et al
    Epidermal growth factor receptor-targeted near-infrared photoimmunotherapy for malignant pleural mesothelioma.
    Lung Cancer. 2026;217:109427.
    PubMed         Abstract available

  35. WANG H, Cai Y, Jiang K, Zou W, et al
    Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.
    Lung Cancer. 2026;217:109412.
    PubMed         Abstract available

  36. ZHANG P, Kuang Y, Jia B, Tian Z, et al
    SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.
    Lung Cancer. 2026;217:109417.
    PubMed         Abstract available

  37. ORTEGA-FRANCO A, Houda I, Brandao M, Pierret T, et al
    Upfront management of brain metastases in oncogene?addicted NSCLC - An EORTC survey.
    Lung Cancer. 2026;217:109444.
    PubMed         Abstract available

  38. HUO Z, Liu K, Zhao D, Wang F, et al
    Dynamic contrast-enhanced and intravoxel incoherent motion magnetic resonance imaging to assess early response of microwave ablation in lung tumors.
    Lung Cancer. 2026;217:109446.
    PubMed         Abstract available

  39. ZHANG J, Liu R, Hui Q, Chen Y, et al
    OX40(+) regulatory T cells suppress neoadjuvant chemotherapy response in NSCLC and reversed by combination of PD-1 blockade therapy.
    Lung Cancer. 2026;217:109458.
    PubMed         Abstract available

  40. HARUTANI Y, Akamatsu H, Sugimoto T, Takakura T, et al
    Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).
    Lung Cancer. 2026;217:109454.
    PubMed         Abstract available

  41. SATO T, Hamamoto J, Emoto K, Nagashio R, et al
    Epigenomic profiling of neuroendocrine lung cancers identifies a classical-neuroendocrine ASCL1/NKX2-1 subtype and a SOX11-associated differentiation axis linked to reduced immunogenicity.
    Lung Cancer. 2026;217:109464.
    PubMed         Abstract available

  42. TSUKADA A, Tsurumaki N, Nishimura N, Nokihara H, et al
    Efficacy and safety of immunotherapy in advanced pulmonary large-cell neuroendocrine carcinoma: A systematic review and meta-analysis.
    Lung Cancer. 2026;217:109468.
    PubMed         Abstract available

  43. PAVLICKOVA K, Hojny J, Hajkova N, Waldauf P, et al
    Comparison of protein-based and genetic prognostic markers in a large cohort of primary pulmonary and extrapulmonary small cell neuroendocrine carcinoma.
    Lung Cancer. 2026;217:109466.
    PubMed         Abstract available

  44. KOBA H, Tambo Y, Murase Y, Yoh K, et al
    Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report.
    Lung Cancer. 2026;218:109492.
    PubMed         Abstract available


    Mol Carcinog

  45. ZHOU Y, Hu Z, Xie L, Zhang W, et al
    Comprehensive Multi-Omics Profiling of Tertiary Lymphoid Structures Reveals Immunogenetic Landscapes and Prognostic Subtypes in Lung Adenocarcinoma.
    Mol Carcinog. 2026;65:888-903.
    PubMed         Abstract available


    Nat Genet

  46. SUN D, Zhang L, Han T, Wu Q, et al
    Accurate, scalable and cross-platform cell identification for high-resolution spatial transcriptomics.
    Nat Genet. 2026;58:1434-1445.
    PubMed         Abstract available


    Nat Med

  47. DING DY, Bot VA, Chen KL, Groves JW, et al
    Plasma proteomic signatures of cellular aging predict human disease.
    Nat Med. 2026;32:2060-2072.
    PubMed         Abstract available

  48. TROST F, Zhang B, Aring I, Bauer M, et al
    An agentic framework for autonomous scientific discovery in cancer pathology.
    Nat Med. 2026;32:2254-2266.
    PubMed         Abstract available


    Oncologist

  49. TAN Y, Wang T, Yu J, Ouyang W, et al
    Dynamic therapeutic response to osimertinib and immunotherapy in an EGFR L747S and L858R co-mutant NSCLC.
    Oncologist. 2026;31:oyag227.
    PubMed         Abstract available

  50. KIM J, Stephan LU, Steinestel K, Tamal YA, et al
    Transformation of ALK-translocated lung adenocarcinoma to LCNEC under alectinib treatment - a case report and mini-review.
    Oncologist. 2026;31:oyag226.
    PubMed         Abstract available


    PLoS Biol

  51. ANOBILE DP, Barbar L, Maucotel E, Cornec A, et al
    Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancer.
    PLoS Biol. 2026;24:e3003860.
    PubMed         Abstract available


    PLoS One

  52. YAO J, Zhou C, Ding L
    KYNU in macrophages contributes to the unique immune feature of LUAD via integrating single-cell and bulk RNA sequencing data: an exploratory analysis.
    PLoS One. 2026;21:e0351622.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  53. KIELISZEK AM, Apel E, Zheng S, Piotrowski M, et al
    Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function.
    Proc Natl Acad Sci U S A. 2026;123:e2603440123.
    PubMed         Abstract available

  54. ZHANG J, Liu R, Han X, Jiao Y, et al
    High-throughput screening identifies a critical role of the SPOP-PABPC1 axis in lung adenocarcinoma progression.
    Proc Natl Acad Sci U S A. 2026;123:e2602470123.
    PubMed         Abstract available


    Thorax

  55. MASCARENHAS E, Cordeiro de Lima VC
    Sex differences in immunotherapy for lung cancer: balance or bias?
    Thorax. 2026 Jun 17:thorax-2026-225209. doi: 10.1136/thorax-2026-225209.
    PubMed        

  56. EVISON M, Ahmed T, Chitnis M, Ward R, et al
    Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017-2025.
    Thorax. 2026;81:707-717.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum